Loading...
XNYS
AVTR
Market cap7.45bUSD
Dec 05, Last price  
10.93USD
1D
-1.97%
1Q
-17.88%
IPO
-29.07%
Name

Avantor Inc

Chart & Performance

D1W1MN
XNYS:AVTR chart
P/E
10.47
P/S
1.10
EPS
1.04
Div Yield, %
Shrs. gr., 5y
11.19%
Rev. gr., 5y
2.35%
Revenues
6.78b
-2.64%
4,909,600,000636,900,000691,300,0001,247,400,0005,864,300,0006,040,300,0006,393,600,0007,386,100,0007,512,400,0006,967,200,0006,783,600,000
Net income
712m
+121.58%
686,500,00021,600,000-42,400,000-112,700,000-86,900,00037,800,000116,600,000572,600,000686,500,000321,100,000711,500,000
CFO
841m
-3.36%
843,600,000124,600,00072,900,000-167,500,000200,500,000354,000,000929,800,000953,600,000843,600,000870,000,000840,800,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
IPO date
May 17, 2019
Employees
14,500
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT